title: Long-term follow-up in dogs with idiopathic eosinophilic bronchopneumopathy treated with inhaled steroid therapy.
abstract: BACKGROUND
  Treatment of canine idiopathic eosinophilic bronchopneumopathy mainly consists of long-term oral corticosteroid therapy. To avoid side effects, inhaled steroid therapy has been increasingly used but long-term clinical response and potential side effects are sparsely described.
  
  
  OBJECTIVE
  Description of clinical response and side effects with long-term fluticasone in dogs with eosinophilic bronchopneumopathy.
  
  
  METHODS
  Case series of dogs with eosinophilic bronchopneumopathy and treated with fluticasone monotherapy for at least 6 months. Clinical response and side effects assessed by physical examination, standardised questionnaire and ACTH (corticotropin) stimulation test.
  
  
  RESULTS
  Eight dogs were treated for between 6 months and 5 years. Cough initially improved in all dogs; two dogs remained free of clinical signs, three were well controlled, but three showed severe relapse. Pituitary-adrenal axis inhibition occurred in two dogs treated with fluticasone monotherapy for more than 2 years; only one dog had clinical signs of iatrogenic hyperadrenocorticism.
  
  
  CONCLUSIONS
  Fluticasone monotherapy allows initial improvement or remission in the majority of dogs but long-term treatment fails to resolve the cough in some individuals. In addition, such therapy may induce pituitary-adrenal axis inhibition. Prospective larger and randomised studies including both fluticasone and orally-treated dogs are needed to define the optimal treatment.
authors.affiliation: Department of Small Animal Clinical Sciences, Internal Medicine, Faculty of Veterinary Medicine, University of Liège, Liège 4000, Belgium. mcanonne@ulg.ac.be.
authors.forename: A M
authors.initials: AM
authors.lastname: Canonne
authors.affiliation: Department of Small Animal Clinical Sciences, Diagnostic Imaging, Faculty of Veterinary Medicine, University of Liège, Liège 4000, Belgium.
authors.forename: G
authors.initials: G
authors.lastname: Bolen
authors.affiliation: Department of Small Animal Clinical Sciences, Internal Medicine, Faculty of Veterinary Medicine, University of Liège, Liège 4000, Belgium.
authors.forename: D
authors.initials: D
authors.lastname: Peeters
authors.affiliation: Department of Small Animal Clinical Sciences, Internal Medicine, Faculty of Veterinary Medicine, University of Liège, Liège 4000, Belgium.
authors.forename: F
authors.initials: F
authors.lastname: Billen
authors.affiliation: Department of Small Animal Clinical Sciences, Internal Medicine, Faculty of Veterinary Medicine, University of Liège, Liège 4000, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Clercx
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001996:Bronchopneumonia / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D003371:Cough / Q000188:drug therapy / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D000068298:Fluticasone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D008297:Male; D011657:Pulmonary Eosinophilia / Q000188:drug therapy / Q000662:veterinary*
chemical_list: D001993:Bronchodilator Agents; D000068298:Fluticasone